Biogen Idec, Inc. (Massachusetts) Profit Falls on Charges, Tysabri Sales Rise

Reuters -- Biogen Idec Inc said on Tuesday that its first-quarter earnings fell 11 percent, hurt by one-time charges, though sales of its multiple sclerosis drugs rose.

MORE ON THIS TOPIC